Chongqing Pharmaceutical recently announced that it completed the cancellation procedures for 15.4066 million repurchased shares on July 8, 2026. The cancelled repurchased shares accounted for 0.8915% of the total share capital before cancellation. After the cancellation, the total share capital decreased from 1.728 billion shares to 1.713 billion shares. The company previously approved a repurchase plan to use its own funds and special loans to repurchase shares through centralized bidding for capital reduction, with a total repurchase amount of no less than 80 million yuan and no more than 100 million yuan, and a repurchase price not exceeding 6.6 yuan per share. As of July 2, 2026, the company had repurchased a total of 15.4066 million shares, with the highest transaction price at 5.48 yuan per share and the lowest at 5.01 yuan per share, paying approximately 80.9988 million yuan. The repurchase plan has been fully implemented. The company stated that this cancellation will not have a significant impact on its operations, finances, research and development, debt repayment capabilities, or future development.
C.Q. Pharmaceutical Holding Co LtdCompany completed cancellation of repurchased shares, reducing share count and potentially increasing EPS.